Abstract
Receptor activator of NF-kB (RANK) and its ligand, receptor activator of NF-kB ligand (RANKL) play a crucial role in the differentiation and activation of osteoclasts. In order to evaluate the efficacy of RANK, we designed a soluble murine RANK (sRANK) and compared its functional activitywith Osteoprotegerin (OPG), a soluble decoy receptor for RANKL. sRANK was expressed in baculovirus-infected Sf-9 cells and purified by Ni-NTA chromatography followed by MonoQ column elution. The binding affinity of the purified sRANK to RANKL was quite similar to that of OPG. Furthermore, the inhibitory effect on RANKL-induced osteoclastogenesis from mouse bone marrow cells showed no significant difference between sRANK and OPG. However, sRANK had no effect on TNF-related apoptosisinducing ligand (TRAIL) -induced apoptosis, although OPG prevented the cytotoxic activity of TRAIL. The results of this study suggest that recombinant sRANK may have therapeutic value as an inhibitor of bone resorption.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
